CM

Cell MedX CorpOOTC CMXC Stock Report

Last reporting period 29 Feb, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.008

Micro

Exchange

OOTC - OTC

CMXC Stock Analysis

CM

Uncovered

Cell MedX Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-58/100

Low score

Market cap $B

0.008

Dividend yield

Shares outstanding

62.923 B

Cell MedX Corp. is a biotech company, which engages in the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. The company is headquartered in Carson City, Nevada. The company went IPO on 2013-03-11. The company is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, general health, pain relief, wellness and alleviate complications associated with medical conditions including, diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney function. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling.

View Section: Eyestock Rating